Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dr. Reddy's Laboratories Ltd ADR (NY: RDY ) 81.22 +0.38 (+0.47%) Official Closing Price Updated: 7:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Dr. Reddy's Laboratories Ltd ADR < Previous 1 2 3 4 5 6 Next > Dr. Reddy’s Q1FY25 Financial Results Today 9:51 EDT From Dr. Reddy’s Laboratories Ltd. Via Business Wire Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem July 10, 2024 Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 Via MarketBeat Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)? July 01, 2024 DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) can be considered a quality stock. Here's why. Via Chartmill Dr. Reddy's Labs Stock Sees Improved Technical Strength June 28, 2024 On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76. Via Investor's Business Daily Dr Reddy's Laboratories: Q3 Earnings Insights January 30, 2024 Via Benzinga Is NYSE:RDY suited for quality investing? September 14, 2023 Exploring DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)'s quality characteristics. Via Chartmill Should you consider NYSE:RDY for quality investing? August 21, 2023 DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) may be suited for quality investing, we'll explore why in this article. Via Chartmill Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M June 26, 2024 Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth... Via Benzinga Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business June 26, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities June 03, 2024 From Aurigene Pharmaceutical Services Ltd. Via Business Wire Chart Of The Day: What's Cooking At Dr. Reddy's Lab July 28, 2023 100% technical buy signals 12 new highs and up 10.76% in the last month 38.40+ Weighted Alpha Via Talk Markets India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High. June 03, 2024 Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections. Via Investor's Business Daily Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America May 28, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Alvotech Via GlobeNewswire RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024 May 07, 2024 RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024. Via InvestorPlace Dr. Reddy’s Q4 & Full Year FY24 Financial Results May 07, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S. May 03, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK March 19, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand February 22, 2024 Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Dr. Reddy’s Q3 & 9M FY24 Financial Results January 31, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands January 03, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index December 14, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) December 06, 2023 From Coya Therapeutics, Inc. Via Business Wire 2 overlooked stocks that crushed earnings but traded lower November 20, 2023 As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results Via MarketBeat Exposures Product Safety Dr. Reddy’s Q2 FY24 Financial Results October 27, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities. October 24, 2023 Reasonable Growth, Debt Levels, and a High ROIC Make DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Appealing to Quality Investors. Via Chartmill Top 5 Health Care Stocks That May Fall Off A Cliff August 23, 2023 The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. Via Benzinga Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. August 10, 2023 From Dr. Reddy's Laboratories Ltd. Via Business Wire Dr. Reddy’s Q1 FY24 Financial Results July 26, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.